Drug Overdose: Clinical Trials

160 trials for Drug Overdose, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

88 completed, 19 unknown, 17 recruiting, 14 active not recruiting. 82 Not applicable, 15 Phase 1, 13 Phase 4, 8 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Not applicable82Completed 45, Active not recruiting 12, Recruiting 10, Not yet recruiting 6, Unknown 5, Withdrawn 3, Enrolling by invitation 1
Phase 115Completed 12, Unknown 2, Recruiting 1
Phase 413Completed 7, Recruiting 2, Withdrawn 2, Active not recruiting 1, Unknown 1
Phase 28Completed 3, Not yet recruiting 2, Terminated 2, Recruiting 1
Phase 32Completed 1, Withdrawn 1
Early Phase 11Completed 1

Follow Drug Overdose: new trials by email Literature Review of Drug Overdose trials Research Report on Drug Overdose

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Permanent Supportive Housing Overdose Prevention+ Study
TA Intervention - Overdose, Substance Use
Not applicableNot yet recruitingNYU Langone Health29402027-07-012026-05-06
Naloxone for Opioid Associated Out of Hospital Cardiac Arrest
Naloxone 2 MG, Saline 2ml - Heart Arrest, Out-Of-Hospital, Opioid Overdose
Phase 2Not yet recruitingUniversity of California, San Francisco982027-03-012026-09-11
The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study
Community Paramedic Standard of Care (CP SOC), CROSSROADS - Opioid Use Disorder, Overdose, Drug
Not applicableNot yet recruitingDuke University4002027-02-012026-10-14
Clinician Practice Companion to Address Youth Substance Use
Practice Companion - Substance Use, Substance-Related Disorders
Not applicableNot yet recruitingMassachusetts General Hospital602027-01-012026-10-07
Disease Intervention Specialist (DIS) for SUD
Substance Use Disorder (SUD), Opioid Use Disorder
Not yet recruitingOhio State University12002026-12-012026-10-15
A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk Aim 3
Brief youth overdose prevention education, Usual Standard of Care - Overdose
Not applicableNot yet recruitingBoston Medical Center6482026-11-012026-10-01
Evaluation of Clinical Decision Support in Opioid Tapering
Observational study without a prospective intervention - Medication Abuse, Harm Reduction
Not yet recruitingUniversity of Colorado, Denver2000002026-11-012026-09-30
HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking
Sex Trafficking Survivor-Developed Digital Crowdsourced Intervention - HIV Testing, STI
Not applicableNot yet recruitingColumbia University3682026-10-012026-01-28
A Bundled Intervention to End Opioid Overdoses
Bundled intervention (Experimental), control group, Buprenorphine (Experimental) - Opioid Use Disorder, Opioid Overdose
Phase 4RecruitingUniversity of Alabama at Birmingham1602026-09-072026-10-02
Overdose Prevention Centers and Behavioral Health
Overdose
Not yet recruitingNYU Langone Health5002026-09-012026-03-02
Behavioral Safety and Fentanyl Education: BSAFE
BSAFE Intervention, Attention control - Drug Overdose, Drug Overdose Accidental
Not applicableRecruitingSan Francisco Department of Public Health1602026-08-112026-08-18
The ENHANCE Project Toolkit
Connections mHealth Application - Substance Related Disorder, Drug Overdose
Not applicableRecruitingUniversity of Wisconsin, Madison402026-07-012026-10-16
Justice Community Overdose Innovation Network II TCU Hub
Core-interagency community engagement approach, Enhanced-Core plus community engagement specialist - Substance Use Disorder (SUD), Drug Overdose
Not applicableNot yet recruitingTexas Christian University16202026-07-012026-04-14
Kentucky Women's Justice Community Overdose Innovation Network - Phase II
Overdose Prevention Intervention Package (OPIP) - Overdose Risk, Opioid Use Disorder
Not applicableRecruitingMichele Staton3002026-06-232026-09-16
Pharmacokinetic (PK) Evaluation of Nalmefene Formulations
Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection - Opioid Overdose
Phase 1CompletedKnoa Pharma LLC132026-02-062026-06-05
Serious Game to Teach Opioid Overdose Response
Serious game training - Opioid Overdose
Phase 2Not yet recruitingUniversity of Nevada, Reno8502026-02-012024-12-11
Trauma-informed Intervention to Reduce Substance Use and to Support Community Transition
TAU + TRUST, TAU + TRUST + Re-entry Recovery Support, Treatment as Usual (TAU) - Substance Use Disorder (SUD)
Not applicableEnrolling by invitationMichele Staton2642025-12-092026-06-09
UnityPhilly Response App for Overdose Reversal
UnityPhilly app - Opioid Overdose
Not applicableRecruitingDrexel University4502025-09-162026-07-20
A Model to Save Lives Through a Volunteer First Responder Service Providing Antidote Treatment in Opioid Overdose
Naloxone-responder: A volunteer first responder system connected to emergency dispatch service and alerting overdose and first aid educated volunteers with naloxone to suspected opioid overdoses - Opioid Overdose
Not applicableRecruitingRegion Skane10002025-09-012025-12-17
A Universal Primary Care Based Intervention to Reduce Youth Overdose Risk
Brief youth overdose prevention education, Information about Naloxone, Usual standard of care - Overdose
Not applicableActive not recruitingBoston Medical Center222025-08-252026-08-07

Showing 20 of 160. Sign in to see all of them.

Narrower conditions

Opiate Overdose (68)  ·  Opioid-Related Disorders (50)  ·  Substance-Related Disorders (34)  ·  Harm Reduction (14)  ·  HIV Infections (5)  ·  Respiratory Insufficiency (5)  ·  Alcoholism (4)  ·  Risk-Taking (4)  ·  Behavior, Addictive (3)  ·  Chemically-Induced Disorders (3)  ·  Emergencies (3)  ·  Mental Disorders (3)  ·  Sexually Transmitted Diseases (3)  ·  Suicide (3)

Broader conditions

Drug Misuse (160)  ·  Prescription Drug Misuse (160)  ·  Chemically-Induced Disorders (157)  ·  Mental Disorders (157)  ·  Substance-Related Disorders (126)  ·  Narcotic-Related Disorders (95)  ·  Opioid-Related Disorders (46)  ·  Behavior (29)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Pathologic Processes (11)  ·  Infections (9)  ·  Respiratory Tract Diseases (9)  ·  Urogenital Diseases (8)  ·  Communicable Diseases (7)

Interventions

Naloxone (17)  ·  Therapeutics (5)  ·  nalmefene (5)  ·  Buprenorphine (3)  ·  Buprenorphine, Naloxone Drug Combination (3)  ·  Injections, Intramuscular (3)  ·  Benzodiazepines (2)  ·  Control Groups (2)  ·  Remifentanil (2)  ·  Saline Solution (2)  ·  Sodium Chloride (2)  ·  Surveys and Questionnaires (2)  ·  4-methylpiperazine-2,6-dione (1)  ·  Acetaminophen (1)  ·  Acetylcysteine (1)

Sponsors

Kaiser Permanente (6)  ·  Norwegian University of Science and Technology (6)  ·  NYU Langone Health (5)  ·  Brown University (4)  ·  Johns Hopkins Bloomberg School of Public Health (4)  ·  University of Alabama at Birmingham (4)  ·  University of Michigan (4)  ·  University of Pennsylvania (4)  ·  New York State Psychiatric Institute (3)  ·  RTI International (3)  ·  Region Skane (3)  ·  San Francisco Department of Public Health (3)  ·  University of Cincinnati (3)  ·  University of Colorado, Denver (3)  ·  VA Office of Research and Development (3)

Countries

United States (119)  ·  Canada (7)  ·  Norway (6)  ·  United Kingdom (6)  ·  Denmark (4)  ·  Sweden (4)  ·  France (3)  ·  Spain (3)  ·  Poland (2)  ·  Austria (1)  ·  China (1)  ·  Egypt (1)  ·  Germany (1)  ·  Iran (1)  ·  Italy (1)

Top investigators

Toril A Nagelhus Hernes, phd prof (4)  ·  Brandon DL Marshall, PhD (3)  ·  Ingrid Binswanger, MD (3)  ·  Jason Glanz, PhD (3)  ·  Theresa Winhusen, PhD (3)  ·  Amy Yule, MD (2)  ·  Carl Latkin, PhD (2)  ·  David J Lowe, MBChB BMSc FRCEM (2)  ·  Gary Smith, MD, DRPH (2)  ·  Joseph A Simonetti, MD MPH (2)  ·  Kelly Doran, MD (2)  ·  Li Li, MD;PhD (2)  ·  Nichole Michaels, PhD (2)  ·  Stephen Lankenau, PhD (2)  ·  Stephen McNulty, DO (2)

Results publications

PMID 21323558, PMID 22847602, PMID 22974490, PMID 22988840, PMID 23556549, PMID 23932166, PMID 24290406, PMID 26810758, PMID 27004905, PMID 27062245, PMID 28113004, PMID 28144724, PMID 28893306, PMID 29049282, PMID 29436397, PMID 29568976, PMID 30143830, PMID 30621699, PMID 30837247, PMID 31556537, PMID 31722937, PMID 32028921, PMID 32651887, PMID 32954238, PMID 33059200, PMID 33070058, PMID 33086156, PMID 33091842, PMID 33091843, PMID 33091844, PMID 33103603, PMID 33184084, PMID 33243291, PMID 33651243, PMID 33978598, PMID 34009877, PMID 34223388, PMID 34236298, PMID 34301246, PMID 34729851, PMID 34758881, PMID 34991359, PMID 35122753, PMID 35132556, PMID 35137493, PMID 35151024, PMID 35212639, PMID 35296414, PMID 35386013, PMID 35587832

NIH funding

R01DA042059 (3), 2014 (2), R61DA057610 (2), R61DA062217 (2), 1IK2HX002861-01A2 (1), 1RM1DA064502 (1), 1UF1MH121949-01 (1), 1UM1DA049394 (1), 1UM1DA049406 (1), 1UM1DA049412 (1), 1UM1DA049415 (1), 1UM1DA049417 (1), 2009 (1), 2015 (1), 2016 (1)